Cargando…

Early Detection of Therapeutic Benefit from PD-1/PD-L1 Blockade in Advanced Lung Cancer by Monitoring Cachexia-Related Circulating Cytokines

SIMPLE SUMMARY: Cancer cachexia is a metabolic disorder that is associated with poor immunotherapeutic outcomes. However, the circulating cachexia-related cytokines have yet to be longitudinally examined to assess their role in predicting the therapeutic outcomes of PD-1/PD-L1 blockade in advanced l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Shiting, Miura, Keita, Shukuya, Takehito, Harada, Sonoko, Fujioka, Masahiro, Winardi, Wira, Shimamura, Shoko, Kurokawa, Kana, Sumiyoshi, Issei, Miyawaki, Taichi, Asao, Tetsuhiko, Mitsuishi, Yoichiro, Tajima, Ken, Takahashi, Fumiyuki, Hayashi, Takuo, Harada, Norihiro, Takahashi, Kazuhisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954513/ https://www.ncbi.nlm.nih.gov/pubmed/36831513 http://dx.doi.org/10.3390/cancers15041170

Ejemplares similares

Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients?
por: Shimamura, Shoko Sonobe, et al.
Publicado: (2022)

Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC: A Systematic Review and Meta-Analysis
por: Xu, Shiting, et al.
Publicado: (2022)

CALML5 is a novel diagnostic marker for differentiating thymic squamous cell carcinoma from type B3 thymoma
por: Kanamori, Koichiro, et al.
Publicado: (2023)

Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study
por: Kurokawa, Kana, et al.
Publicado: (2022)

Activation of insulin‐like growth factor‐1 receptor confers acquired resistance to osimertinib in non‐small cell lung cancer with EGFR T790M mutation
por: Hayakawa, Daisuke, et al.
Publicado: (2019)

Zinc‐finger E‐box‐binding homeobox 1 (ZEB1) plays a crucial role in the maintenance of lung cancer stem cells resistant to gefitinib
por: Nurwidya, Fariz, et al.
Publicado: (2021)

Clinical characteristics of adrenal insufficiency induced by pembrolizumab in non‐small‐cell lung cancer
por: Kurokawa, Kana, et al.
Publicado: (2022)

Impact of the generation of EGFR‐TKIs administered as prior therapy on the efficacy of osimertinib in patients with non‐small cell lung cancer harboring EGFR T790M mutation
por: Miyashita, Yosuke, et al.
Publicado: (2020)

SCLC-J1, a novel small cell lung cancer cell line
por: Ohara, Kazuo, et al.
Publicado: (2021)

Clinical impact of tumour burden on the efficacy of PD‐1/PD‐L1 inhibitors plus chemotherapy in non‐small‐cell lung cancer
por: Miyawaki, Taichi, et al.
Publicado: (2022)

Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease
por: Kato, Motoyasu, et al.
Publicado: (2014)

Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC
por: Miyawaki, Taichi, et al.
Publicado: (2020)

Impact of losing adipose tissue on outcomes from PD‐1/PD‐L1 inhibitor monotherapy in non‐small cell lung cancer
por: Nishioka, Naoya, et al.
Publicado: (2022)

Predicting the efficacy of first‐line immunotherapy by combining cancer cachexia and tumor burden in advanced non‐small cell lung cancer
por: Miyawaki, Taichi, et al.
Publicado: (2022)

Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy
por: Akamatsu, Hiroaki, et al.
Publicado: (2014)

TWEAK enhances TGF-β-induced epithelial-mesenchymal transition in human bronchial epithelial cells
por: Itoigawa, Yukinari, et al.
Publicado: (2015)

Severe mediastinitis over a month after endobronchial ultrasound‐guided transbronchial needle aspiration
por: Kurokawa, Kana, et al.
Publicado: (2019)

Highly sensitive fusion detection using plasma cell‐free RNA in non‐small‐cell lung cancers
por: Hasegawa, Nobuhiko, et al.
Publicado: (2021)

Epidemiology, risk factors and impact of cachexia on patient outcome: Results from the Japanese Lung Cancer Registry Study
por: Shukuya, Takehito, et al.
Publicado: (2023)

Hermansky-Pudlak syndrome-associated pneumothorax with rapid progression of respiratory failure: a case report
por: Kato, Yukari, et al.
Publicado: (2020)

Tocilizumab, a Proposed Therapy for the Cachexia of Interleukin6-Expressing Lung Cancer
por: Ando, Katsutoshi, et al.
Publicado: (2014)

Positive PD-L1 Expression Predicts Worse Outcome in Cutaneous Angiosarcoma
por: Shimizu, Akira, et al.
Publicado: (2016)

PD-L1 expression in malignant salivary gland tumors
por: Harada, Koji, et al.
Publicado: (2018)

Transformation from adenocarcinoma to squamous cell lung carcinoma with MET amplification after lorlatinib resistance: A case report
por: Ueda, Shoko, et al.
Publicado: (2021)

Anaphylaxis to three humanized antibodies for severe asthma: a case study
por: Jingo, Koichi, et al.
Publicado: (2020)

Cerebral infarction in advanced non-small cell lung cancer: a case control study
por: Kato, Motoyasu, et al.
Publicado: (2016)

Mobile Health App for Japanese Adult Patients With Asthma: Clinical Observational Study
por: Harada, Norihiro, et al.
Publicado: (2020)

Quantitative immunohistochemical assay with novel digital immunostaining for comparisons of PD-L1 antibodies
por: Fujisawa, Takuo, et al.
Publicado: (2019)

Dramatic, significant metabolic response to a one‐time pembrolizumab treatment following a relapse of pre‐existing organizing pneumonia in a patient with advanced non‐small cell lung cancer: A case report
por: Kato, Motoyasu, et al.
Publicado: (2021)

Prognostic impact of serum CYFRA 21–1 in patients with advanced lung adenocarcinoma: a retrospective study
por: Ono, Akira, et al.
Publicado: (2013)

Successful restart of chemotherapy in a patient with primary mediastinal nonseminomatous germ cell tumor after COVID‐19 infection
por: Tanabe, Yuki, et al.
Publicado: (2022)

GFORCE-PD still going strong in 2016
por: Parmar, Malin, et al.
Publicado: (2017)

Remarkable response to nivolumab in sarcomatoid malignant pleural mesothelioma with high PD‐L1
por: Tsubouchi, Kazuya, et al.
Publicado: (2020)

Relapsing Polychondritis following PD-1 Blockade by an Immune Checkpoint Inhibitor
por: Mutoh, Tomoyuki, et al.
Publicado: (2023)

Hochuekkito (TJ-41), a Kampo Formula, Ameliorates Cachexia Induced by Colon 26 Adenocarcinoma in Mice
por: Yae, Suzu, et al.
Publicado: (2012)

Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers
por: Okadome, Kazuo, et al.
Publicado: (2020)

Electric dipole effect in PdCoO(2)/β-Ga(2)O(3) Schottky diodes for high-temperature operation
por: Harada, T., et al.
Publicado: (2019)

Efficacy and Safety of PD-1/PD-L1 Inhibitor as Single-Agent Immunotherapy in Endometrial Cancer: A Systematic Review and Meta-Analysis
por: Mamat @ Yusof, Mohd Nazzary, et al.
Publicado: (2023)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study
por: Rounis, Konstantinos, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5uduuhlhs7scoac37nbm993nbq